[go: up one dir, main page]

BRPI0918004A2 - antagonistas de glucagon - Google Patents

antagonistas de glucagon

Info

Publication number
BRPI0918004A2
BRPI0918004A2 BRPI0918004A BRPI0918004A BRPI0918004A2 BR PI0918004 A2 BRPI0918004 A2 BR PI0918004A2 BR PI0918004 A BRPI0918004 A BR PI0918004A BR PI0918004 A BRPI0918004 A BR PI0918004A BR PI0918004 A2 BRPI0918004 A2 BR PI0918004A2
Authority
BR
Brazil
Prior art keywords
glucagon antagonists
glucagon
antagonists
Prior art date
Application number
BRPI0918004A
Other languages
English (en)
Inventor
Haiqing Li
Jorge E Gomez-Galeno
Mali Venkat Reddy
Matthew P Grote
Qun Dang
Robert Huerta Lemus
Scott J Hecker
Thanh Huu Nguyen
Zhili Sun
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of BRPI0918004A2 publication Critical patent/BRPI0918004A2/pt
Publication of BRPI0918004B1 publication Critical patent/BRPI0918004B1/pt
Publication of BRPI0918004B8 publication Critical patent/BRPI0918004B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pain & Pain Management (AREA)
BRPI0918004A 2008-08-13 2009-08-13 compostos antagonistas e agonistas inversos de receptores de glucagon, composição farmacêutica e uso dos compostos BRPI0918004B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8869708P 2008-08-13 2008-08-13
PCT/US2009/053795 WO2010019830A1 (en) 2008-08-13 2009-08-13 Glucagon antagonists

Publications (3)

Publication Number Publication Date
BRPI0918004A2 true BRPI0918004A2 (pt) 2015-11-17
BRPI0918004B1 BRPI0918004B1 (pt) 2019-08-13
BRPI0918004B8 BRPI0918004B8 (pt) 2021-05-25

Family

ID=41350634

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918004A BRPI0918004B8 (pt) 2008-08-13 2009-08-13 compostos antagonistas e agonistas inversos de receptores de glucagon, composição farmacêutica e uso dos compostos

Country Status (13)

Country Link
US (4) US8907103B2 (pt)
EP (3) EP2326618B1 (pt)
JP (5) JP5684126B2 (pt)
KR (2) KR101634515B1 (pt)
CN (2) CN104803891B (pt)
BR (1) BRPI0918004B8 (pt)
CA (2) CA2966273C (pt)
DK (1) DK2799428T3 (pt)
ES (3) ES2714207T3 (pt)
MX (1) MX2011001708A (pt)
PL (1) PL2799428T3 (pt)
PT (1) PT2799428T (pt)
WO (1) WO2010019830A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033634A (en) * 1989-04-03 1991-07-23 The Procter & Gamble Company Child resistant container for storing hazardous materials
KR20160052792A (ko) 2007-02-09 2016-05-12 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
EP2326618B1 (en) * 2008-08-13 2014-10-15 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2012085745A1 (en) 2010-12-23 2012-06-28 Pfizer Inc. Glucagon receptor modulators
EP2673260B1 (en) 2011-02-08 2016-08-17 Pfizer Inc Glucagon receptor modulator
JP5647379B2 (ja) 2011-07-22 2014-12-24 ファイザー・インク キノリニルグルカゴン受容体モジュレーター
WO2015191900A1 (en) * 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN106336387A (zh) * 2015-07-10 2017-01-18 浙江海正药业股份有限公司 酰胺类衍生物、其制备方法及其在医药上的用途
US20170143673A1 (en) * 2015-11-24 2017-05-25 Remd Biotherapeutics, Inc. Methods For Treating Heart Failure Using Glucagon Receptor Antagonists
EP3500565A1 (en) * 2016-08-17 2019-06-26 Ligand Pharmaceuticals, Inc. Glucagon receptor antagonists
JP6937524B2 (ja) * 2017-01-24 2021-09-22 昊運股▲フン▼有限公司Ａｌｐｈａｌａ Ｃｏ．， Ｌｔｄ アミド化合物およびその使用
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
KR102176621B1 (ko) 2018-08-21 2020-11-10 가천대학교 산학협력단 페닐피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524846A (en) 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5322951B2 (pt) 1974-06-05 1978-07-12
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
JPH0738070B2 (ja) 1986-07-25 1995-04-26 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
EP0284240B2 (en) 1987-03-09 1993-06-16 EASTMAN KODAK COMPANY (a New Jersey corporation) Photographic silver halide materials and process comprising a pyrazolotriazole coupler
JPH081079B2 (ja) 1987-10-12 1996-01-10 大和ハウス工業株式会社 複数階の構造物
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
JP3347723B2 (ja) 1990-06-13 2002-11-20 グラツィエル，アーノルド 含リンプロドラッグ
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH05322951A (ja) 1992-05-26 1993-12-07 Toshiba Corp トリップシーケンスログ装置
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE69426904T2 (de) 1993-06-29 2001-10-11 Mitsubishi Chemical Corp., Tokio/Tokyo Phosphonat-Nukleotid Ester-Derivate
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5780058A (en) 1995-07-21 1998-07-14 Alza Corporation Oral delivery of discrete units
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
JPH09241284A (ja) 1996-03-08 1997-09-16 Koji Yamashita 新規なオキシアザホスホリン誘導体
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
JPH1197740A (ja) 1997-09-19 1999-04-09 Showa Denko Kk ＧａＰ発光ダイオード用エピタキシャルウェーハおよびＧａＰ発光ダイオード
KR100576583B1 (ko) 1997-12-22 2006-05-04 알자 코포레이션 서방성 약물 송달 장치용 속도 조절막
WO1999033446A1 (en) 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
EP1051217B8 (en) 1997-12-31 2004-07-21 ALZA Corporation Osmotic drug delivery monitoring system
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
RU2246295C2 (ru) 1998-11-02 2005-02-20 Элзэ Копэрейшн Лекарственная форма c постоянной скоростью высвобождения лекарственного вещества, ядро лекарственной формы и способ обеспечения облегченного высвобождения лекарственного вещества из лекарственной формы
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
CA2373892A1 (en) * 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
CA2374793A1 (en) 1999-05-24 2000-11-30 Penglie Zhang Inhibitors of factor xa
EP1214324B1 (en) 1999-09-10 2006-06-14 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
DE10008329A1 (de) 2000-02-23 2001-08-30 Merck Patent Gmbh Aminosulfonylbiphenylderivate
BR0111908A (pt) 2000-06-23 2003-04-01 Novo Nordisk As Composto, composição farmacêutica, uso do composto, e, método para o tratamento e/ou prevenção de distúrbios ou doenças
WO2002040444A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
JP2005511683A (ja) * 2001-12-03 2005-04-28 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
US20030212119A1 (en) 2001-12-20 2003-11-13 Jesper Lau Novel glucagon receptor antagonists/inverse agonists
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
EP1569915A4 (en) 2002-12-04 2007-07-11 Merck & Co Inc SPIROCYCLIC UREA, COMPOSITIONS CONTAINING THESE COMPOUNDS AND METHOD OF USE
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
US20040152750A1 (en) 2002-12-20 2004-08-05 Kodra Janos Tibor Novel glucagon antagonists
EP1590336B1 (en) 2003-01-27 2010-12-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
US7138529B2 (en) 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
AU2004238240A1 (en) 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
JP2007512359A (ja) 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
EP1690538A4 (en) 2003-12-02 2009-02-25 Shionogi & Co ISOXAZOLE DERIVATIVE AGONISTIC ACTION AGAINST PEROXISOM PROLIFERATOR ACTIVATED RECEPTOR
JP2007514794A (ja) 2003-12-19 2007-06-07 メルク　エンド　カムパニー　インコーポレーテッド 環式グアニジン、そのような化合物を含む組成、及び使用方法
US20070015757A1 (en) 2003-12-19 2007-01-18 Novo Nordisk A/S Novel Glucagon Antagonists/Inverse Agonists
WO2005118542A1 (en) 2004-05-28 2005-12-15 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
DE602005006806D1 (de) 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
CN1968921B (zh) 2004-06-14 2011-11-23 伊莱利利公司 胰高血糖素受体拮抗剂、制备和治疗用途
WO2006002361A2 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
EP1765335B1 (en) 2004-07-07 2009-11-25 Merck & Co., Inc. Pyrazole amide derivatives, compositions containing such compounds and methods of use
DE602005021494D1 (de) 2004-07-22 2010-07-08 Merck Sharp & Dohme Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
MX2007009661A (es) 2005-02-11 2007-09-25 Lilly Co Eli Derivados de tiofeno substituidos como antagonistas del receptor de glucagon, preparacion y usos terapeuticos.
JP2008533200A (ja) 2005-03-21 2008-08-21 メルク エンド カムパニー インコーポレーテッド 置換アリールおよびヘテロアリール誘導体、かかる化合物を含有する組成物および使用法
WO2006104826A2 (en) 2005-03-30 2006-10-05 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR100738004B1 (ko) 2005-05-23 2007-07-13 (주)주빅스테크놀러지 하이브리드 ｐ2ｐ 네트워크 지능형 분산 컴파일러 시스템및 그 방법과 상기 방법을 실현시키기 위한 프로그램을기록한 컴퓨터로 읽을 수 있는 기록매체
CA2614537A1 (en) 2005-07-26 2007-02-08 Merck & Co., Inc. Process for synthesizing a substituted pyrazole
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
AU2006340002B2 (en) 2005-11-17 2011-12-22 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
EP1951658B1 (en) 2005-11-17 2012-09-26 Eli Lilly & Company Glucagon receptor antagonists, preparation and therapeutic uses
BRPI0618484A2 (pt) 2005-11-18 2011-08-30 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de glucagon em um mamìfero, para reduzir seletivamente o nìvel glicêmico em um mamìfero e para tratar diabete tipo 2, e, uso de um composto ou um sal do mesmo
EP1957068B1 (en) 2005-11-22 2014-08-13 Eli Lilly & Company Glucagon receptor antagonists, preparation and therapeutic uses
CA2629311C (en) 2005-11-23 2014-05-06 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
AU2007229850A1 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2019585A2 (en) 2006-05-16 2009-02-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7512570B2 (en) 2006-05-30 2009-03-31 Zaracom Technologies Inc. Artificial intelligence analyzer and generator
EP2045253A4 (en) 2006-06-29 2013-01-23 Nissan Chemical Ind Ltd alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient
TW200821284A (en) * 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8519145B2 (en) 2006-12-02 2013-08-27 Seoul National University Industry Foundation Aryl compounds as PPAR ligands and their use
KR20160052792A (ko) 2007-02-09 2016-05-12 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
EP2326618B1 (en) 2008-08-13 2014-10-15 Metabasis Therapeutics, Inc. Glucagon antagonists
EP2734207A4 (en) 2011-07-18 2015-06-17 Tokai Pharmaceuticals Inc NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROSTATE CANCER
US8869708B1 (en) 2011-08-26 2014-10-28 Daniel P. Meyer Model railroad flashing rear end device
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
JP2017051900A (ja) 2015-09-08 2017-03-16 国立大学法人横浜国立大学 触媒とその製造方法
CN205117265U (zh) 2015-11-19 2016-03-30 北京美高科技发展有限公司 电缆式电液控制割管工具

Also Published As

Publication number Publication date
JP6309076B2 (ja) 2018-04-11
CN102292316A (zh) 2011-12-21
US20150087680A1 (en) 2015-03-26
EP2799428A2 (en) 2014-11-05
EP2326618A1 (en) 2011-06-01
JP2012500212A (ja) 2012-01-05
KR101599089B1 (ko) 2016-03-02
EP2799428B1 (en) 2016-11-16
BRPI0918004B8 (pt) 2021-05-25
EP3153501B1 (en) 2018-11-28
JP2018083834A (ja) 2018-05-31
BRPI0918004B1 (pt) 2019-08-13
US10221130B2 (en) 2019-03-05
US20130030029A1 (en) 2013-01-31
ES2527670T3 (es) 2015-01-28
JP2015129133A (ja) 2015-07-16
MX2011001708A (es) 2011-04-26
CA2770298C (en) 2017-06-20
HK1203481A1 (en) 2015-10-30
EP2799428A3 (en) 2014-12-17
CA2966273A1 (en) 2010-02-18
CN102292316B (zh) 2015-07-01
CN104803891B (zh) 2017-10-20
CA2770298A1 (en) 2010-02-18
PL2799428T3 (pl) 2017-05-31
JP5684126B2 (ja) 2015-03-11
US11352321B2 (en) 2022-06-07
KR20150118203A (ko) 2015-10-21
CN104803891A (zh) 2015-07-29
EP2326618B1 (en) 2014-10-15
JP2019112427A (ja) 2019-07-11
PT2799428T (pt) 2017-02-17
DK2799428T3 (da) 2017-02-20
ES2615481T3 (es) 2017-06-07
ES2714207T3 (es) 2019-05-27
KR20110042357A (ko) 2011-04-26
JP2017101039A (ja) 2017-06-08
EP3153501A1 (en) 2017-04-12
JP6490843B2 (ja) 2019-03-27
US20190330144A1 (en) 2019-10-31
US8907103B2 (en) 2014-12-09
KR101634515B1 (ko) 2016-06-28
CA2966273C (en) 2019-08-27
WO2010019830A1 (en) 2010-02-18
US9783494B2 (en) 2017-10-10
US20180022695A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
DK2370461T3 (da) Glucagonanaloger
NO2018009I1 (no) Dupilumab
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
BRPI0823377A2 (pt) análogos de glucagon
BRPI0823378A2 (pt) análogos de glucagon
BRPI0823376A2 (pt) Análagos de glucagon
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
BRPI0918004A2 (pt) antagonistas de glucagon
EP2303378A4 (en) INTERFACE
BRPI0907376A2 (pt) Fotobiorretador
HRP20151108T1 (xx) Antagonisti nogo-receptora
BRPI0810926A2 (pt) Antagonista de crig
BRPI0907522A2 (pt) biarlamidas
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
BR112012005119A2 (pt) novos antagonistas de hepcidina etanodiaminas
BRPI0907519A2 (pt) Antagonistas farmacoforos-pde4-muscarínicos duais
DK2386008T3 (da) Gelænderkonstruktion
BRPI0822880A2 (pt) alfa-mercapto-amidas
FI20090462A0 (fi) Kaiderakenne
FI20080591A0 (fi) Eleillä ohjattava käyttöliittymä
AT504815A3 (de) Geländer
UA17510S (uk) Балясина
UA17527S (uk) Балясина
UA17512S (uk) Балясина
UA17515S (uk) Балясина

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2009, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2632 DE 15-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.